Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at UBS Group AG from $70.00 to $96.00. They now have a "neutral" rating on the stock.
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Mizuho from $90.00 to $100.00. They now have an "outperform" rating on the stock.
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Daiwa America to a "hold" rating.
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study [Yahoo! Finance]
How Gilead Is Driving Global Health Equity And Innovation [Forbes]